Alto Neuroscience (ANRO) Competitors $3.89 +0.17 (+4.57%) (As of 12/20/2024 04:32 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ANRO vs. RGNX, ALMS, AKBA, CYRX, PROC, NGNE, BTMD, VYGR, DSGN, and CTNMShould you be buying Alto Neuroscience stock or one of its competitors? The main competitors of Alto Neuroscience include REGENXBIO (RGNX), Alumis (ALMS), Akebia Therapeutics (AKBA), Cryoport (CYRX), Procaps Group (PROC), Neurogene (NGNE), biote (BTMD), Voyager Therapeutics (VYGR), Design Therapeutics (DSGN), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry. Alto Neuroscience vs. REGENXBIO Alumis Akebia Therapeutics Cryoport Procaps Group Neurogene biote Voyager Therapeutics Design Therapeutics Contineum Therapeutics REGENXBIO (NASDAQ:RGNX) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, community ranking, institutional ownership, analyst recommendations, profitability and media sentiment. Does the media refer more to RGNX or ANRO? In the previous week, Alto Neuroscience had 4 more articles in the media than REGENXBIO. MarketBeat recorded 5 mentions for Alto Neuroscience and 1 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.88 beat Alto Neuroscience's score of 0.23 indicating that REGENXBIO is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alto Neuroscience 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of RGNX or ANRO? 88.1% of REGENXBIO shares are held by institutional investors. 13.1% of REGENXBIO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is RGNX or ANRO more profitable? Alto Neuroscience has a net margin of 0.00% compared to REGENXBIO's net margin of -283.19%. Alto Neuroscience's return on equity of -49.28% beat REGENXBIO's return on equity.Company Net Margins Return on Equity Return on Assets REGENXBIO-283.19% -70.65% -41.68% Alto Neuroscience N/A -49.28%-33.52% Do analysts recommend RGNX or ANRO? REGENXBIO presently has a consensus target price of $35.27, indicating a potential upside of 362.90%. Alto Neuroscience has a consensus target price of $20.00, indicating a potential upside of 414.14%. Given Alto Neuroscience's higher possible upside, analysts plainly believe Alto Neuroscience is more favorable than REGENXBIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score REGENXBIO 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.63 Does the MarketBeat Community believe in RGNX or ANRO? REGENXBIO received 422 more outperform votes than Alto Neuroscience when rated by MarketBeat users. However, 82.35% of users gave Alto Neuroscience an outperform vote while only 65.96% of users gave REGENXBIO an outperform vote. CompanyUnderperformOutperformREGENXBIOOutperform Votes43665.96% Underperform Votes22534.04% Alto NeuroscienceOutperform Votes1482.35% Underperform Votes317.65% Which has preferable valuation and earnings, RGNX or ANRO? Alto Neuroscience has lower revenue, but higher earnings than REGENXBIO. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioREGENXBIO$84.33M4.48-$263.49M-$5.03-1.51Alto Neuroscience$210K499.59-$36.31MN/AN/A SummaryAlto Neuroscience beats REGENXBIO on 8 of the 15 factors compared between the two stocks. Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANRO vs. The Competition Export to ExcelMetricAlto NeurosciencePharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$100.33M$6.57B$5.12B$19.18BDividend YieldN/A2.98%4.91%3.59%P/E RatioN/A10.5991.3441.28Price / Sales499.59195.381,116.5917.59Price / CashN/A57.1642.6421.28Price / BookN/A5.104.795.32Net Income-$36.31M$151.51M$120.07M$989.88M7 Day Performance1.57%-2.15%-1.89%-3.54%1 Month Performance-5.70%-3.14%11.45%-3.68%1 Year PerformanceN/A11.50%30.61%12.14% Alto Neuroscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANROAlto Neuroscience3.2602 of 5 stars$3.89+4.6%$20.00+414.1%N/A$100.33M$210,000.000.00N/AGap UpRGNXREGENXBIO4.5991 of 5 stars$8.56+3.4%$35.27+312.1%-58.4%$410.23M$84.33M-1.70344ALMSAlumisN/A$8.68+3.5%$26.83+209.1%N/A$409.89MN/A0.00N/AAnalyst ForecastLockup ExpirationNews CoveragePositive NewsAKBAAkebia Therapeutics3.3979 of 5 stars$1.86+0.3%$7.50+304.3%+52.5%$404.73M$169.88M-8.15167News CoverageCYRXCryoport3.0208 of 5 stars$7.70+0.1%$12.50+62.3%-49.8%$380.62M$226.11M-2.321,170Analyst ForecastGap DownPROCProcaps Group0.891 of 5 stars$3.31+37.3%N/A-20.3%$373.43M$414.10M5.105,500News CoverageHigh Trading VolumeNGNENeurogene3.74 of 5 stars$24.67+4.9%$60.83+146.6%N/A$366.47M$925,000.000.0090BTMDbiote3.2446 of 5 stars$6.60+3.6%$9.11+38.0%+20.8%$358.62M$193.06M24.77194Positive NewsGap UpVYGRVoyager Therapeutics4.6047 of 5 stars$6.50+3.7%$17.00+161.5%-27.6%$355.10M$250.01M8.83100DSGNDesign Therapeutics0.926 of 5 stars$6.25+11.6%$7.00+12.0%+143.2%$353.88MN/A-7.1840News CoverageCTNMContineum Therapeutics1.9464 of 5 stars$13.60-3.1%$29.25+115.1%N/A$350.58M$50M0.0031News Coverage Related Companies and Tools Related Companies REGENXBIO Competitors Alumis Competitors Akebia Therapeutics Competitors Cryoport Competitors Procaps Group Competitors Neurogene Competitors biote Competitors Voyager Therapeutics Competitors Design Therapeutics Competitors Contineum Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:ANRO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANRO Stock Alerts